The art of developing potential anticancer molecules involves a reasonable selection of core moiety and tethering with biologically active pharmacophores. We report a library of rationally designed twelve triazole tethered benzimidazole molecules as novel potential inhibitors for cancer. Their synthesis followed a facile copper-catalysed cycloaddition reaction with good yields. Although in-silico molecular docking studies of the synthesized compounds with epigenetic protein viz., PRMTs showed inhibition, the compounds bearing amino acid and aryl groups exhibited excellent performance. The potential anti-cancer activity of the library of molecules are further evaluated in vitro against the selected cancer cell lines (MCF-7, DU145, PC3 and HepG2) besides methylation assays. In vitro results revealed that the compounds bearing amino acid and aryl groups exhibited better activity and particularly, 3-CF 3 -phenyl derivative (IC 50 = 4.11 μm against MCF-7) exerted prominent anticancer potency against all the tested cell lines. The observed strong anticancer potency of lead compound is supported by its strong binding nature noted in in-silico molecular docking studies.